PTSM: Pharmaceutical Technology Sourcing and Management, Jun 6, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, Jun 6, 2012
Global Feature
Big Pharma's Mid-Year Review
By Patricia Van Arnum
The key activity of the pharmaceutical majors influencing drug development and manufacturing thus far in 2012.
Biotech
An Uneven Path for Biotech Financing
By Patricia Van Arnum
Venture-capital funding is up in 2012, but public financing remains sluggish in the biopharmaceutical industry.
Outsourcing
Channeling Steve Jobs
Service providers must focus on delivering a superior customer experience.
APIs
Seeking Chemocatalytic and Biocatalytic Solutions
By Patricia Van Arnum
Advances in palladium-catalyzed hydrogenation, visible-light photocatalysis, and chemocatalyisis for heterocycles are some recent developments.
Drug Delivery
Technical Insights: Targeted Drug Delivery
By Patricia Van Arnum
Needle-free jet injection systems, gold-coated nanoparticles, and elastic capsules with nanosized flakes advance targeted drug delivery.
CSR and Sustainability Forum
CSR and Sustainability in the News
A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.
Pharma Industry Responds to Global Health Initiatives
By Patricia Van Arnum
The pharmaceutical industry weighs in on WHO global health initiatives, including R&D for diseases of the developing world, a global vaccine action plan, neglected tropical diseases, and counterfeit medicines.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here